Recursion Pharmaceuticals (RXRX) just delivered encouraging Phase 1b/2 TUPELO data for its FAP drug candidate REC-4881, and that clinical update has quickly reshaped how both Wall Street and ...

Abstract: Rain streaks in outdoor images can severely affect the performance of high-level vision tasks, such as surveillance and autonomous driving, by obscuring important image details. The ...

Dec 8 (Reuters) - Recursion Pharma (RXRX.O), opens new tab, which uses artificial intelligence to discover new drug candidates, said on Monday its experimental oral drug helped reduce abnormal growths ...

Amid an outpouring of obesity data Monday, Wave Life Sciences and Structure Therapeutics were among the biotechs jockeying to set their weight loss assets apart in an increasingly crowded field as ...

How is AI and data leadership at large organizations being transformed by the accelerating pace of AI adoption? Do these leaders’ mandates need to change? And should overseeing AI and data be viewed ...

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.71. LONDON — In the year-plus since Najat Khan joined the AI-focused drug ...

Function Health, a startup that offers lab testing and body scans for early disease detection, scored nearly $300 million in series B funding, boosting its valuation to $2.5 billion. Redpoint Ventures ...

From electronic health records and blood tests to the stream of data from wearable devices, the amount of health information people generate is accelerating rapidly. Yet, many users struggle to ...

After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week. Can R&D chief and new CEO Najat Khan turn it around? In 2014, Recursion ...

The new managed functions will let enterprises apply LLM reasoning to structured and unstructured data directly in SQL, eliminating prompt tuning and external tools. Google has boosted its BigQuery ...

Investors in Recursion (NASDAQ: RXRX) seemed only mildly fazed by Wednesday’s series of company announcements. The artificial intelligence (AI)-based drug developer’s stock barely moved on Wednesday, ...

The delayed release of the BLS report has led to fearmongering about the economy's ability to function. Leila Fadel, host of NPR's Up First, said on Friday that "businesses and policymakers are flying ...